FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.

Hospital

FibroGen

Michael D. Lowenstein

Mark Lonergan

Elias Kouchakji

Pat Cotroneo

Leanne C. Price

Percy H. Carter

Christine L. Chung

Thane Wettig

Dr. Olga V. Gambetti M.D., Ph.D., Drmedsci

Lori S.

Aileen Huang (Cuihua)

Juan Graham

Chris Newman

Simon Miller

Carol Gaddum

Claudia Witschi

Sarah Helgeson

Elena Vaisberg

Faeq Mansour

Tricia Stewart

Dongxia Li

Dana Fong

Gerardo Pangilinan Ms, Dabt

Guangjie Guo

Gihani Wijewickrama

Jung Min Park

Krithica Sanjana

Zhao Hongda

Bernardo Lomongsod

Rudy C. Tadina

Yinan Zhang

Jack Li

Dennis Kim

Van Pell Gerard

Michelle Deng-Rao

Wenqi You

Javier Moreno

Leadership Team

Clinical Development Team

Information Technology Team

Legal and Compliance Team

Teams at FibroGen

Leadership Team

Clinical Development Team

Information Technology Team

Legal and Compliance Team